Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I GnP chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma
jRCTs041180147Phase 1Completed
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC). Primary endpoint: dose-limiting toxicity. Started Feb 2018; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041180147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180147.